Cognitive decline in post-COVID-19 syndrome does not correspond with persisting neuronal or astrocytic damage

Fabian Boesl,Yasemin Goereci,Finja Schweitzer,Carsten Finke,Ann-Katrin Schild,Stefan Bittner,Falk Steffen,Maria Schröder,Anneke Quitschau,Josephine Heine,Clemens Warnke,Christiana Franke
DOI: https://doi.org/10.1038/s41598-024-55881-1
IF: 4.6
2024-03-06
Scientific Reports
Abstract:Cognitive impairment is the most frequent symptom reported in post-COVID-19 syndrome (PCS). Aetiology of cognitive impairment in PCS is still to be determined. Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are increased in acute COVID-19. Their role as biomarkers in other neurological disorders is under debate. We analysed serum levels of NfL and GFAP as markers for neuronal and astrocytic damage in 53 patients presenting to a PCS Neurology outpatient clinic. Only individuals with self-reported cognitive complaints were included. In these individuals, cognitive complaints were further assessed by comprehensive neuropsychological assessment (NPA). Patients were categorized into subgroups of subjective cognitive decline, single domain impairment, or multi-domain impairment. Serum NfL was in normal range, however an increase of serum GFAP was detected in 4% of patients. Serum NfL and GFAP levels correlated with each other, even when adjusting for patient age (r = 0.347, p = 0.012). NPA showed deficits in 70%; 40% showing impairment in several tested domains. No significant differences were found between serum NfL- and GFAP-levels comparing patients with subjective cognitive decline, single domain impairment, or multi-domain impairment. Persistent neuronal or astrocytic damage did not correlate with cognitive impairment in PCS.
multidisciplinary sciences
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: whether cognitive impairment in Post - COVID - 19 Syndrome (PCS) is related to persistent neuronal or astrocytic damage. Specifically, the researchers analyzed the levels of Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) in the sera of 53 patients who visited the neurology outpatient clinic due to PCS. These two proteins are markers of neuronal and astrocytic damage respectively. All individuals included in the study had self - reported cognitive impairment, and the specific conditions of these cognitive impairments were further evaluated through a comprehensive Neuropsychological Assessment (NPA). The main purpose of the study was to explore whether cognitive impairment is associated with persistent neuronal or astrocytic damage in PCS patients. By analyzing the serum levels of NfL and GFAP and the relationship between these biomarkers and cognitive impairment, the researchers hope to reveal the underlying biological mechanisms of cognitive impairment in PCS.